Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) have been given an average rating of “Moderate Buy” by the thirteen research firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $55.5556.

Several analysts recently commented on TERN shares. Wall Street Zen cut shares of Terns Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, January 17th. UBS Group raised shares of Terns Pharmaceuticals to a “strong-buy” rating in a report on Thursday, December 4th. Barclays lifted their price target on shares of Terns Pharmaceuticals from $36.00 to $56.00 and gave the company an “overweight” rating in a research report on Tuesday, December 9th. Truist Financial upped their price target on Terns Pharmaceuticals from $35.00 to $56.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. Finally, JMP Securities set a $35.00 price objective on Terns Pharmaceuticals in a report on Wednesday, November 26th.

Terns Pharmaceuticals Price Performance

Shares of TERN stock opened at $34.33 on Friday. The business’s fifty day moving average price is $36.04 and its 200 day moving average price is $18.01. The firm has a market capitalization of $3.09 billion, a PE ratio of -33.33 and a beta of -0.28. Terns Pharmaceuticals has a 1-year low of $1.87 and a 1-year high of $48.26.

Terns Pharmaceuticals (NASDAQ:TERN) last released its earnings results on Monday, November 10th. The company reported ($0.27) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.03. Equities research analysts expect that Terns Pharmaceuticals will post -1.19 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Emil Kuriakose sold 1,155 shares of the stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $38.57, for a total value of $44,548.35. Following the sale, the insider directly owned 50,365 shares of the company’s stock, valued at approximately $1,942,578.05. This represents a 2.24% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Amy L. Burroughs sold 71,339 shares of the firm’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $38.10, for a total transaction of $2,718,015.90. Following the transaction, the chief executive officer owned 138,976 shares of the company’s stock, valued at $5,294,985.60. This trade represents a 33.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 165,763 shares of company stock worth $5,752,450 over the last 90 days. 1.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Terns Pharmaceuticals

Several large investors have recently modified their holdings of TERN. GAMMA Investing LLC increased its stake in shares of Terns Pharmaceuticals by 762.4% during the 4th quarter. GAMMA Investing LLC now owns 871 shares of the company’s stock worth $35,000 after purchasing an additional 770 shares in the last quarter. FNY Investment Advisers LLC purchased a new stake in Terns Pharmaceuticals in the 4th quarter valued at approximately $80,000. The Manufacturers Life Insurance Company grew its holdings in Terns Pharmaceuticals by 8.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 27,262 shares of the company’s stock valued at $102,000 after buying an additional 2,097 shares during the last quarter. Velan Capital Investment Management LP increased its position in Terns Pharmaceuticals by 17.6% during the second quarter. Velan Capital Investment Management LP now owns 20,000 shares of the company’s stock worth $75,000 after buying an additional 3,000 shares in the last quarter. Finally, Intech Investment Management LLC raised its holdings in shares of Terns Pharmaceuticals by 15.5% in the second quarter. Intech Investment Management LLC now owns 46,121 shares of the company’s stock worth $172,000 after acquiring an additional 6,199 shares during the last quarter. 98.26% of the stock is currently owned by institutional investors and hedge funds.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.